{
    "clinical_study": {
        "@rank": "10022", 
        "acronym": "C-TALK", 
        "brief_summary": {
            "textblock": "This is a post-marketing, observational, non-interventional, multi-central study of patients\n      with non-small cell lung cancer (NSCLC), with data collected prospectively from medical\n      records at inclusion. The primary objective is to obtain the epidemiologic data of\n      anaplastic lymphoma kinase (ALK)-positive in unselected Chinese patients with NSCLC."
        }, 
        "brief_title": "A Prospective Epidemiologic Study of ALK-Positive NSCLC in China", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Archived paraffin-embedded and fresh frozen NSCLC tumor tissue will be obtained via the\n      Department of Pathology. ALK positive status will be detected by Ventana\n      immunohistochemistry (IHC) (Ventana Medical Systems, Inc. and Roche Diagnostics\n      International, Inc). When ALK positive patients are detected, crizotinib will be\n      administrated by various solutions based on physician's desecration and patients'\n      willingness.\n\n      The secondary objectives include: 1.To obtain the epidemiologic data of ALK positive in\n      unselected Chinese patients with NSCLC.2.To describe demographic, socioeconomic [such as\n      age, gender, race/ethnicity, geographic location (including rural/urban area), pathologic\n      parameters, education, family income, National Reimbursement Drug List (NRDL) or Provincial\n      Reimbursement List (PRDL)], and clinical characteristics of NSCLC patients with ALK\n      positive.\n\n      The exploratory objective is to describe prognosis patterns associated with crizotinib\n      treated patients when efficacy data are available non-interventionally."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (\u226518 years), both sex.\n\n          -  Histologically or cytologically proven diagnosis of primary NSCLC, including squamous\n             cell carcinoma and adenocarcinoma.\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Those lung cancers without pathological diagnosis should not be included in case of\n             other types of cancer, including small cell lung cancer (SCLC) or metastatic disease\n             from other organs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "unselected Chinese patients with non-small-cell lung cancer"
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042105", 
            "org_study_id": "CTONG1303"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non-small-cell lung cancer", 
            "anaplastic lymphoma kinase", 
            "immunohistochemistry"
        ], 
        "lastchanged_date": "January 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "yangjinji2003@163.com", 
                    "last_name": "Jin-Ji Yang, MD", 
                    "phone": "+86 20 83827812", 
                    "phone_ext": "50810"
                }, 
                "contact_backup": {
                    "email": "gzzhouqing@126.com", 
                    "last_name": "Qing Zhou, MD", 
                    "phone": "+86 20 83827812", 
                    "phone_ext": "51221"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510080"
                    }, 
                    "name": "Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Jin-Ji Yang, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yangjinji2003@163.com", 
                    "last_name": "Jin-Ji Yang, MD", 
                    "phone": "86 20 83827812", 
                    "phone_ext": "50810"
                }, 
                "contact_backup": {
                    "email": "gzzhouqing@126.com", 
                    "last_name": "Qing Zhou, MD", 
                    "phone": "86 20 83827812", 
                    "phone_ext": "51221"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510080"
                    }, 
                    "name": "Guangdong General Hospital"
                }, 
                "investigator": {
                    "last_name": "Yi-Long Wu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China", 
        "other_outcome": {
            "measure": "prognosis patterns associated with crizotinib treated patients when efficacy data are available non-interventionally.", 
            "safety_issue": "No", 
            "time_frame": "one and half years"
        }, 
        "overall_contact": {
            "email": "yangjinji2003@163.com", 
            "last_name": "Jin-Ji Yang, MD", 
            "phone": "+86 20 83827812", 
            "phone_ext": "50810"
        }, 
        "overall_contact_backup": {
            "email": "gzzhouqing@126.com", 
            "last_name": "Qing Zhou, MD", 
            "phone": "+86 20 83827812", 
            "phone_ext": "51221"
        }, 
        "overall_official": [
            {
                "affiliation": "Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences", 
                "last_name": "Yi-Long Wu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Guangdong General Hospital", 
                "last_name": "Yi-Long Wu, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the frequency of ALK rearrangement in unselected Chinese patients with non-small cell lung cancer", 
            "safety_issue": "No", 
            "time_frame": "one and half years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "demographic, socioeconomic,clinical and pathological features of ALK-positive NSCLC patients", 
            "safety_issue": "No", 
            "time_frame": "one and half years"
        }, 
        "source": "Guangdong Association of Clinical Trials", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong Association of Clinical Trials", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}